Researchers conducted a Phase 1/2 trial to test a specific drug combination in patients who are unfit for standard transplants. The study included 36 patients in the first part and 30 randomized patients in the second part, all having newly diagnosed multiple myeloma. The main goal was to see if the drugs worked safely in this vulnerable group.
The results indicated that 97.6% of patients had an overall response to the treatment. Furthermore, 83% of patients were still progression-free at 18 months, and 97.2% had not progressed by the end of the follow-up period. Median survival times had not been reached yet during the study period.
Safety was a major focus, particularly regarding eye problems known as ocular adverse events. While these events occurred, less than 1% of patients stopped driving or reading because of them. The impact on quality of life appeared limited, suggesting the side effects were manageable for most people.
Readers should understand that this is early evidence from a small group of people. While the regimen looks effective, it is not yet a standard option. A larger Phase 3 study is needed to confirm these findings and determine if this treatment should be widely used.
